Pharsight

Apadaz is owned by Kvk Tech Inc.

Apadaz contains Acetaminophen; Benzhydrocodone Hydrochloride.

Apadaz has a total of 5 drug patents out of which 0 drug patents have expired.

Apadaz was authorised for market use on 23 February, 2018.

Apadaz is available in tablet;oral dosage forms.

Apadaz can be used as management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

The generics of Apadaz are possible to be released after 22 February, 2031.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9132125	KVK TECH INC	Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof	Jul, 2030 (7 years from now)
US9549923	KVK TECH INC	Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and uses thereof	Jul, 2030 (7 years from now)
US8748413	KVK TECH INC	Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof	Jul, 2030 (7 years from now)
US8461137	KVK TECH INC	Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof	Feb, 2031 (8 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8828978	KVK TECH INC	Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof	Jul, 2030 (7 years from now)